Profile data is unavailable for this security.
About the company
Biodexa Pharmaceuticals PLC is a United Kingdom-based clinical-stage biopharmaceutical company. The Company is developing a pipeline of products for the treatment of diseases with unmet medical needs. Its technologies include Biodexa Pharmaceuticals Q-Sphera, MidaCore and MidaSolve. The Q-Sphera technology focuses on long-acting injectables using proprietary three-dimensional (3D) printing technology that encapsulates medicines into bioresorbable polymer microspheres with precision characteristics. The MidaCore technology platform uses ultra-small gold nanoparticle (GNP) drug conjugates. The MidaSolve Nano Inclusion technology solubilizes molecules that have minimal solubility biological potential of Hydrogen (pH), extending available routes of administration, including direct-to-tumor delivery. Its pipeline includes MTX110, MTD201, MTD211 (Schizophrenia, MDD), MTX223, and MTD217.
- Revenue in USD (TTM)484.02k
- Net income in USD-8.99m
- Incorporated2014
- Employees21.00
- LocationBiodexa Pharmaceuticals PLC1 Caspian Point, Caspian WayABINGDON CF10 4DQUnited KingdomGBR
- Phone+44 123 584 1575
- Websitehttps://www.biodexapharma.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Portage Biotech Inc | 0.00 | -144.90m | 5.45m | 7.00 | -- | 0.1703 | -- | -- | -7.96 | -7.96 | 0.00 | 1.62 | 0.00 | -- | -- | 0.00 | -111.60 | -19.70 | -113.27 | -26.48 | -- | -- | -- | -- | -- | -- | 0.0087 | -- | -- | -- | -520.10 | -- | -- | -- |
| Fresh Tracks Therapeutics Inc | 8.01m | -5.69m | 5.48m | 4.00 | -- | 0.5514 | -- | 0.6839 | -1.38 | -1.38 | 1.49 | 1.66 | 0.7326 | -- | -- | 2,001,500.00 | -52.10 | -89.76 | -66.50 | -115.24 | -- | -- | -71.12 | -442.61 | -- | -1,272.00 | 0.00 | -- | 15.31 | 37.62 | 73.02 | -- | -- | -- |
| Palisade Bio Inc | 0.00 | -13.49m | 5.48m | 9.00 | -- | 0.4949 | -- | -- | -24.67 | -24.67 | 0.00 | 11.82 | 0.00 | -- | -- | 0.00 | -96.63 | -132.36 | -111.78 | -165.45 | -- | -- | -- | -27,892.32 | -- | -874.31 | 0.00 | -- | -- | -0.7814 | 13.74 | -- | 18.53 | -- |
| MyMD Pharmaceuticals Inc | 0.00 | -7.07m | 5.49m | 9.00 | -- | 0.2428 | -- | -- | -5.53 | -5.53 | 0.00 | 10.28 | 0.00 | -- | -- | 0.00 | -25.59 | -76.20 | -31.13 | -84.38 | -- | 7.64 | -- | -4,290.96 | -- | -- | 0.00 | -- | -- | -- | 49.15 | -- | -- | -- |
| Processa Pharmaceuticals Inc | 0.00 | -9.83m | 5.54m | 13.00 | -- | 0.6237 | -- | -- | -6.29 | -6.29 | 0.00 | 3.11 | 0.00 | -- | -- | 0.00 | -87.82 | -84.35 | -102.32 | -90.03 | -- | -- | -- | -- | -- | -- | 0.0012 | -- | -- | -- | 59.45 | -- | -34.05 | -- |
| ProtoKinetix, Inc. | 0.00 | -400.47k | 5.55m | 0.00 | -- | 13.99 | -- | -- | -0.0012 | -0.0012 | 0.00 | 0.0011 | 0.00 | -- | -- | -- | -88.14 | -696.88 | -101.62 | -785.51 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 78.22 | -- | 10.78 | -- |
| Biodexa Pharmaceuticals PLC-ADR | 484.02k | -8.99m | 5.57m | 21.00 | -- | 0.6355 | -- | 11.51 | -23.93 | -23.93 | 0.933 | 2.00 | 0.0474 | -- | 0.4638 | 23,048.79 | -88.12 | -69.02 | -164.67 | -88.49 | -- | -- | -1,858.01 | -1,926.06 | -- | -- | 0.0902 | -- | -45.49 | -27.77 | 7.54 | -- | 1.51 | -- |
| Stemtech Corp | 4.64m | -4.08m | 5.59m | 45.00 | -- | -- | -- | 1.20 | -0.0624 | -0.0624 | 0.0619 | -0.0092 | 1.09 | 8.35 | 65.16 | 103,098.40 | -96.70 | -- | -- | -- | 76.09 | -- | -88.58 | -- | 0.1045 | -1.81 | 2.27 | -- | -- | -- | -- | -- | -- | -- |
| Halberd Corp | 281.24k | 25.34k | 5.60m | 3.00 | 3.79 | -- | 220.56 | 19.90 | 0.0023 | 0.0023 | 0.0018 | -0.0002 | 0.1449 | 0.0303 | 2.52 | -- | 1.31 | -- | 4.58 | -- | 50.00 | -- | 9.01 | -- | 0.2661 | 1.35 | 1.02 | -- | 271.52 | -- | -60.11 | -- | -- | -- |
| Biofrontera Inc | 34.07m | -20.13m | 5.60m | 85.00 | -- | 0.3483 | -- | 0.1643 | -15.19 | -15.19 | 24.30 | 3.16 | 0.8646 | 1.93 | 5.42 | 400,858.80 | -51.08 | -- | -101.07 | -- | 48.80 | -- | -59.08 | -- | 0.6727 | -2.71 | 0.4489 | -- | 18.82 | -- | -3,045.47 | -- | -- | -- |
| Ensysce Biosciences Inc | 1.75m | -11.55m | 5.61m | 7.00 | -- | 1.44 | -- | 3.21 | -3.74 | -3.74 | 0.5109 | 0.5115 | 0.3886 | -- | 9.06 | 249,514.30 | -257.00 | -17.68 | -574.02 | -19.42 | -- | -- | -661.34 | -715.78 | -- | -6.25 | 0.0671 | -- | -11.61 | -- | 57.64 | -- | -- | -- |
| Azitra Inc | 572.70k | -12.40m | 5.61m | 10.00 | -- | 1.30 | -- | 9.80 | -2.87 | -2.87 | 0.0492 | 0.1501 | 0.0977 | -- | 11.54 | 57,270.00 | -200.61 | -- | -287.43 | -- | -- | -- | -2,053.34 | -- | -- | -129.02 | 0.0085 | -- | 141.55 | -- | 6.02 | -- | -- | -- |
| Glucose Health Inc | 1.11m | -456.46k | 5.63m | 2.00 | -- | 5.94 | -- | 5.06 | -0.033 | -0.033 | 0.0803 | 0.0561 | -- | -- | -- | -- | -- | -86.94 | -- | -153.95 | 47.19 | 40.68 | -31.99 | -56.93 | 313.11 | -- | 0.00 | -- | 98.39 | 24.94 | 16.87 | -- | -- | -- |
| China Pharma Holdings Inc | 6.42m | -3.56m | 5.67m | 231.00 | -- | 0.6379 | -- | 0.8824 | -0.8352 | -0.8352 | 1.03 | 0.5596 | 0.3828 | 1.93 | 14.14 | 27,795.89 | -21.22 | -29.66 | -44.77 | -55.25 | -11.67 | 6.47 | -55.42 | -73.09 | 0.2523 | -11.34 | 0.261 | -- | -13.48 | -10.68 | 22.50 | -- | -25.78 | -- |
| Silo Pharma Inc | 72.12k | -3.53m | 5.69m | 3.00 | -- | 1.09 | -- | 78.91 | -1.18 | -1.20 | 0.024 | 1.87 | 0.008 | -- | -- | 24,040.00 | -39.26 | -24.90 | -43.11 | -26.39 | 91.90 | 82.79 | -4,889.57 | -2,757.85 | -- | -- | 0.00 | -- | 0.00 | -- | 7.07 | -- | -- | -- |
Data as of May 21 2024. Currency figures normalised to Biodexa Pharmaceuticals PLC's reporting currency: US Dollar USD
8.41%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| GAMMA Investing LLCas of 31 Mar 2024 | 11.10k | 4.23% |
| Bank of America, NA (Private Banking)as of 31 Mar 2024 | 5.24k | 2.00% |
| Cavalry Fund I Management LLCas of 31 Dec 2023 | 2.77k | 1.06% |
| UBS Securities LLCas of 31 Mar 2024 | 2.44k | 0.93% |
| RhumbLine Advisers LPas of 31 Mar 2024 | 498.00 | 0.19% |
| Morgan Stanley & Co. LLCas of 31 Mar 2024 | 16.00 | 0.01% |
| Boothbay Fund Management LLCas of 31 Mar 2024 | 0.00 | 0.00% |
| Renaissance Technologies LLCas of 31 Mar 2024 | 0.00 | 0.00% |
More ▼
Data from 31 Dec 2023 - 31 Mar 2024Source: FactSet Research Systems Inc.
